RhumbLine Advisers’s Verona Pharma VRNA Stock Holding History

RhumbLine Advisers’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-596	Closed	-$63.6K	–	4181
2025 Q3	$63.6K	Buy	596 +84	+16%	+$8.77K	﹤0.01%	3619
2025 Q2	$48.4K	Sell	512 -50	-9%	-$3.7K	﹤0.01%	3671
2025 Q1	$35.7K	Sell	562 -388	-41%	-$23.2K	﹤0.01%	3645
2024 Q4	$44.1K	Sell	950 -8	-0.8%	-$300	﹤0.01%	3670
2024 Q3	$27.6K	Buy	958 +117	+14%	+$2.88K	﹤0.01%	3776
2024 Q2	$12.2K	Buy	841 +343	+69%	+$5.01K	﹤0.01%	3950
2024 Q1	$8.01K	Buy	498 +221	+80%	+$3.82K	﹤0.01%	3907
2023 Q4	$5.5K	Buy	277 +79	+40%	+$1.17K	﹤0.01%	3963
2023 Q3	$3.23K	Buy	198 +45	+29%	+$867	﹤0.01%	4046
2023 Q2	$3.23K	Buy	+153	New	+$3.26K	﹤0.01%	4152

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

RhumbLine Advisers's VRNA Position: Q4 2025 in Review

RhumbLine Advisers sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 596 shares — an estimated $63.6K sold.

RhumbLine Advisers first reported a position in VRNA in Q2 2023 and held it in 10 quarters. The position peaked at $63.6K in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

RhumbLine Advisers reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
RhumbLine Advisers sold 596 Verona Pharma shares in Q4 2025, an estimated $63.6K.
RhumbLine Advisers first reported a position in Verona Pharma in Q2 2023 and held it in 10 quarters.
RhumbLine Advisers's Verona Pharma position peaked at $63.6K in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on RhumbLine Advisers's 13F filing for Q4 2025, filed 13 Feb 2026.